Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- PMID: 19880497
- DOI: 10.1182/blood-2009-07-235358
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Abstract
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.
Similar articles
-
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Blood. 2017. PMID: 27895058 Free PMC article. Review.
-
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. Blood. 2022. PMID: 35797463
-
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.Blood. 2012 Oct 18;120(16):3187-205. doi: 10.1182/blood-2012-03-362608. Epub 2012 Aug 9. Blood. 2012. PMID: 22879540 Review.
-
Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.Med Oncol. 2018 Sep 5;35(11):141. doi: 10.1007/s12032-018-1179-3. Med Oncol. 2018. PMID: 30187210
-
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.Ann Hematol. 2019 Nov;98(11):2467-2483. doi: 10.1007/s00277-019-03820-w. Epub 2019 Oct 30. Ann Hematol. 2019. PMID: 31667544 Review.
Cited by
-
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.Expert Rev Anticancer Ther. 2012 Oct;12(10):1289-97. doi: 10.1586/era.12.116. Expert Rev Anticancer Ther. 2012. PMID: 23176617 Free PMC article.
-
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28. Haematologica. 2015. PMID: 26022709 Free PMC article. Clinical Trial.
-
Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia.Ther Adv Hematol. 2022 Oct 28;13:20406207221132346. doi: 10.1177/20406207221132346. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36324489 Free PMC article.
-
Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats.PLoS One. 2012;7(3):e33213. doi: 10.1371/journal.pone.0033213. Epub 2012 Mar 29. PLoS One. 2012. PMID: 22479372 Free PMC article.
-
Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Curr Hematol Malig Rep. 2013 Jun;8(2):156-62. doi: 10.1007/s11899-013-0158-1. Curr Hematol Malig Rep. 2013. PMID: 23640069 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical